Clinical Study

An Open-Label, Single-Arm Study To Evaluate The Effectiveness And Safety Of Ocrelizumab In Patients With Early Stage Relapsing Remitting Multiple Sclerosis

Posted Date: Jun 27, 2017

  • Investigator: Lawrence Goldstick
  • Co-Investigator: Melissa Rooney
  • Specialties:
  • Type of Study: Observational/Survey

The purpose of this study is to see if ocrelizumab (study drug) will halt the worsening of the signs and symptoms of your early stage MS. Ocrelizumab is a type of drug called a monoclonal antibody. Monoclonal antibodies act like your body’s immune system and attach to certain cells in order to attack germs and other illnesses in your body. Ocrelizumab attaches to certain types of white blood cells (B cells) that are thought to play a role in MS. Ocrelizumab is an experimental drug, which means the health authorities have not approved ocrelizumab for the treatment of MS.

Criteria:

You Are Invited To Take Part In A Research Study (Also Known As A Clinical Trial) Of A Drug Called Ocrelizumab. You Were Selected As A Possible Participant In This Study Because You Have Early Stage Relapsing Remitting Form Of Multiple Sclerosis (Ms).

Keywords:

Monoclonal Antibodies, F. Hoffmann-La Roche Ltd, Multiple Sclerosis, Ocrelizumab, Relapse Remitting

For More Information:

Samantha Maldonado
937-535-5012
samantha.maldonado@uchealth.com

  • Search Clinical Studies

  • Research in the News

    Therapy After Surgical Removal of Rare Tumors May Not Increase Survival

    Results of an analysis show that additional therapy delivered after surgicalremoval of a rare type of gastrointestinal tumor does not increase survivalrates for patients.